WASHINGTON, D.C. (December 11, 2003) - Advance media registration is now open for the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2004, scheduled February 23-25 at the Waldorf-Astoria in New York City. Now in its sixth year, the event will provide an opportunity for key industry players to examine investment opportunities and issues affecting the biotechnology industry.
New to this year's conference are sessions on the advancements and developments in the technology by therapeutic areas. Plenary and business roundtable sessions will be presented by over 200 private and publicly-held biotechnology companies, which will include Amgen, Genentech, MedImmune, Millennium Pharmaceuticals and Gilead Sciences. These sessions will also focus on mergers and acquisitions, Project BioShield, cancer drug clinical trial design, as well as rheumatoid arthritis, Alzheimer's, Parkinson's and diabetes.
Registration is complimentary for credentialed news media. Advance registration is available until February 9, 2004. To register, please visit www.bio.org. Only reporters and editors working full time for print or broadcast news organizations may register onsite with valid media credentials.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.